Table of Content

1 Key Insights

2 Executive summary

3 Organizations

4 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
4.1 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2017
4.2 Total Market Share (%) Distribution of Wet Form Age-related Macular Degeneration (Wet-AMD) in 2030

5 Wet Form Age-related Macular Degeneration (Wet-AMD): Market Overview at a Glance
5.1 Introduction
5.2 Classification and clinical manifestations
5.3 Signs and Symptoms
5.4 Risk factors
5.5 Pathophysiology
5.6 Diagnosis
5.6.1 Patients’ history, clinical examination, and self-monitoring
5.6.2 Angiography
5.6.3 Optical coherence tomography (OCT)

6 Epidemiology and Patient Population
6.1 Key Findings
6.2 Assumptions and Rationale
6.3 Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM
6.4 United States
6.4.1 Total prevalent cases of Wet-AMD in the United States
6.4.2 Gender-specific cases of Wet-AMD in the United States
6.4.3 Age-specific cases of Wet-AMD in the United States
6.5 EU5 Countries
6.6 Germany
6.6.1 Total prevalent cases of Wet-AMD in Germany
6.6.2 Gender-specific cases of Wet-AMD in Germany
6.6.3 Age-specific cases of Wet-AMD in Germany
6.7 France
6.7.1 Total prevalent cases of Wet-AMD in France
6.7.2 Gender-specific cases of Wet-AMD in France
6.7.3 Age-specific cases of Wet-AMD in France
6.8 Italy
6.8.1 Total prevalent cases of Wet-AMD in Italy
6.8.2 Gender-specific cases of Wet-AMD in Italy
6.8.3 Age-specific cases of Wet-AMD in Italy
6.9 Spain
6.9.1 Total prevalent cases of Wet-AMD in Spain
6.9.2 Gender-specific cases of Wet-AMD in Spain
6.9.3 Age-specific cases of Wet-AMD in Spain
6.10. UK
6.10.1 Total prevalent cases of Wet-AMD in the United Kingdom
6.10.2 Gender-specific cases of Wet-AMD in the United Kingdom
6.10.3 Age-specific cases of Wet-AMD in the United Kingdom
6.11 Japan
6.11.1 Total prevalent cases of Wet-AMD in Japan
6.11.2 Gender-specific cases of Wet-AMD in Japan
6.11.3 Age-specific cases of Wet-AMD in Japan

7 Treatment of Wet Form Age-related Macular Degeneration (Wet-AMD)

8 Unmet Needs

9 Marketed drugs
9.1 Eylea: Regeneron Pharmaceuticals
9.1.1 Drug Description
9.1.2 Regulatory Milestones
9.1.3 Other Development Activities
9.1.4 Clinical Development
9.1.5 Safety and Efficacy
9.1.6 Product Profile
9.2 Beovu: Novartis
9.2.1 Drug Description
9.2.2 Regulatory Milestones
9.2.3 Clinical Development
9.2.4 Safety and Efficacy
9.2.5 Product Profile
9.3 Lucentis: Novartis
9.3.1 Drug Description
9.3.2 Regulatory Milestones
9.3.3 Other Development Activities
9.3.4 Clinical Development
9.3.5 Safety and Efficacy
9.3.6 Product Profile
9.4 Macugen: Pfizer
9.4.1 Drug Description
9.4.2 Regulatory Milestones
9.4.3 Other Development Activities
9.4.4 Clinical Development
9.4.5 Safety and Efficacy
9.4.6 Product Profile

10 Emerging Therapies
10.1 Key Cross Competition
10.1.1 Other promising therapies
10.2 Faricimab: Roche
10.2.1 Drug Description
10.2.2 Clinical Development
10.2.3 Safety and Efficacy
10.2.4 Product Profile
10.3 Conbercept: Chengdu Kanghong Biotech
10.3.1 Drug Description
10.3.2 Other Development activities
10.3.3 Clinical Development
10.3.4 Safety and Efficacy
10.3.5 Product Profile
10.4 KSI-301: Kodiak Sciences Inc.
10.4.1 Drug Description
10.4.2 Other Development Activities
10.4.3 Clinical Development
10.4.4 Safety and Efficacy
10.4.5 Product Profile
10.5 OPT-302: Opthea Limited
10.5.1 Drug Description
10.5.2 Other Development Activities
10.5.3 Clinical Development
10.5.4 Safety and Efficacy
10.5.5 Product Profile
10.6 AKST4290: Alkahest Inc
10.6.1 Drug Description
10.6.2 Other Development Activities
10.6.3 Clinical Development
10.6.4 Safety and Efficacy
10.6.5 Product Profile
10.7 Sunitinib Malate: Graybug Vision
10.7.1 Drug Description
10.7.2 Clinical Development
10.7.3 Safety and Efficacy
10.7.4 Product Profile
10.8 RGX-314: REGENXBIO
10.8.1 Drug Description
10.8.2 Other Development Activities
10.8.3 Clinical Development
10.8.4 Safety and Efficacy
10.8.5 Product Profile

11 Other Promising Therapies
11.1 PAN-90806: PanOptica, Inc.
11.1.1 Drug Description
11.1.2 Other Development Activities
11.1.3 Clinical Development
11.1.4 Safety and Efficacy
11.1.5 Product Profile
11.2 Axitinib: Clearside Biomedical
11.2.1 Drug Description
11.2.2 Clinical Development
11.2.3 Safety and Efficacy
11.2.4 Product Profile
11.3 HMR59: Hemera Biosciences
11.3.1 Drug Description
11.3.2 Other Development Activities
11.3.3 Clinical Development
11.3.4 Product Profile
11.4 RBM-007: Ribomic USA Inc
11.4.1 Drug Description
11.4.2 Other Development Activities
11.4.3 Clinical Development
11.4.4 Safety and Efficacy
11.4.5 Product Profile

12 Wet Form Age-related Macular Degeneration (Wet-AMD): 7 Major Market Analysis
12.1 Key Findings
12.2 Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM

13 Seven Major Market Outlook

14 United States Market Size
14.1 Total Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in the United States
14.2 Total Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) by Therapies in the United States
14.3 Germany
14.3.1 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Germany
14.3.2 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) by Therapies in Germany
14.4 France
14.4.1 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) in France
14.4.2 Total Market size of Wet Form Age-related Macular Degeneration (Wet-AMD) by Therapies in France
14.5 Italy
14.5.1 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Italy
14.5.2 Total Market size of Wet Form Age-related Macular Degeneration (Wet-AMD) by Therapies in Italy
14.6 Spain
14.6.1 Total Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Spain
14.6.2 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) by Therapies in Spain
14.7 United Kingdom
14.7.1 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) in the United Kingdom
14.7.2 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) by Therapies in the UK
14.8 Japan
14.8.1 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Japan
14.8.2 Total market size of Wet Form Age-related Macular Degeneration (Wet-AMD) by Therapies in Japan
15 Market Drivers
16 Market Barriers
17 SWOT Analysis
18 Market Access
19 Case Study
19.1 Macular Hole Surgery in the Case of Wet Age-related Macular Degeneration Treated with Intravitreal Aflibercept
19.2 Case Series on Initial Responses to Intravitreal Brolucizumab in Patients with Recalcitrant Chronic Wet Age-related Macular Degeneration
19.3 Association of familial macular degeneration with specific genetic markers: a case report
19.4 Durable recovery of the macular architecture and functionality of a diagnosed Age-related macular degeneration 1 year after a single intravitreal injection of dobesilate
20 KOL Views
21 Bibliography
22 Appendix
22.1 Report Methodology
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight



List of Figures


Figure 1: Mechanism of action of CFH (in normal regulation)
Figure 2: Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM (2017–2030)
Figure 3: Total prevalent cases of Wet-AMD in the United States (2017–2030)
Figure 4: Gender-specific cases of Wet-AMD in the US (2017–2030)
Figure 5: Age-specific cases of Wet-AMD in the US (2017–2030)
Figure 6: Total prevalent cases of Wet-AMD in Germany (2017–2030)
Figure 7: Gender-specific cases of Wet-AMD in Germany (2017–2030)
Figure 8: Age-specific cases of Wet-AMD in Germany (2017–2030)
Figure 9: Total prevalent cases of Wet-AMD in France (2017–2030)
Figure 10: Gender-specific cases of Wet-AMD in France (2017–2030)
Figure 11: Age-specific cases of Wet-AMD in France (2017–2030)
Figure 12: Total prevalent cases of Wet-AMD in Italy (2017–2030)
Figure 13: Gender-specific cases of Wet-AMD in Italy (2017–2030)
Figure 14: Age-specific cases of Wet-AMD in Italy (2017–2030)
Figure 15: Total prevalent cases of Wet-AMD in Spain (2017–2030)
Figure 16: Gender-specific cases of Wet-AMD in Spain (2017–2030)
Figure 17: Age-specific cases of Wet-AMD in Spain (2017–2030)
Figure 18: Total prevalent cases of Wet-AMD in the United Kingdom (2017–2030)
Figure 19: Gender-specific cases of Wet-AMD in the UK (2017–2030)
Figure 20: Age-specific cases of Wet-AMD in the UK (2017–2030)
Figure 21: Total prevalent cases of Wet-AMD in Japan (2017–2030)
Figure 22: Gender-specific cases of Wet-AMD in Japan (2017–2030)
Figure 23: Age-specific cases of Wet-AMD in Japan (2017–2030)
Figure 24: AMD Treatment Guidelines
Figure 25: Unmet Needs
Figure 26: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Figure 27: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in the US, USD Millions (2017–2030)
Figure 28: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in the US by therapies, USD Millions (2017–2030)
Figure 29: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Germany, USD Millions (2017–2030)
Figure 30: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Germany by therapies, USD Millions (2017–2030)
Figure 31: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in France, USD Millions (2017–2030)
Figure 32: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in France by therapies, USD Millions (2017–2030)
Figure 33: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Italy, USD Millions (2017–2030)
Figure 34: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Italy by therapies, USD Millions (2017–2030)
Figure 35: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Spain, USD Millions (2017–2030)
Figure 36: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Spain by therapies, USD Millions (2017–2030)
Figure 37: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in the UK, USD Millions (2017–2030)
Figure 38: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in the UK by therapies, USD Millions (2017–2030)
Figure 39: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Japan, USD Millions (2017–2030)
Figure 40: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Japan by therapies, USD Millions (2017–2030)
Figure 41: Market Drivers
Figure 42: Market Barriers


List of Tables


Table 1: Summary of Wet-AMD Market, Epidemiology, and Key Events (2017–2030)
Table 2: Total cases of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM (2017–2030)
Table 3: Total prevalent cases of Wet-AMD in the United States (2017–2030)
Table 4: Gender-specific cases of Wet-AMD in the US (2017–2030)
Table 5: Age-specific cases of Wet-AMD in the US (2017–2030)
Table 6: Total prevalent cases of Wet-AMD in Germany (2017–2030)
Table 7: Gender-specific cases of Wet-AMD in Germany (2017–2030)
Table 8: Age-specific cases of Wet-AMD in Germany (2017–2030)
Table 9: Total prevalent cases of Wet-AMD in France (2017–2030)
Table 10: Gender-specific cases of Wet-AMD in France (2017–2030)
Table 11: Age-specific cases of Wet-AMD in France (2017–2030)
Table 12: Total prevalent cases of Wet-AMD in Italy (2017–2030)
Table 13: Gender-specific cases of Wet-AMD in Italy (2017–2030)
Table 14: Age-specific cases of Wet-AMD in Italy (2017–2030)
Table 15: Total prevalent cases of Wet-AMD in Spain (2017–2030)
Table 16: Gender-specific cases of Wet-AMD in Spain (2017–2030)
Table 17: Age-specific cases of Wet-AMD in Spain (2017–2030)
Table 18: Total prevalent cases of Wet-AMD in the United Kingdom (2017–2030)
Table 19: Gender-specific cases of Wet-AMD in the UK (2017–2030)
Table 20: Age-specific cases of Wet-AMD in the UK (2017–2030)
Table 21: Total prevalent cases of Wet-AMD in Japan (2017–2030)
Table 22: Gender-specific cases of Wet-AMD in Japan (2017–2030)
Table 23: Age-specific cases of Wet-AMD in Japan (2017–2030)
Table 24: Properties of Anti-VEGF Agents
Table 25: Eylea, Clinical Trial Description, 2020
Table 26: Beovu, Clinical Trial Description, 2020
Table 27: Lucentis, Clinical Trial Description, 2020
Table 28: Faricimab, Clinical Trial Description, 2020
Table 29: Conbercept, Clinical Trial Description, 2020
Table 30: KSI-301, Clinical Trial Description, 2020
Table 31: OPT-302, Clinical Trial Description, 2020
Table 32: AKST4290, Clinical Trial Description, 2020
Table 34: Sunitinib Malate, Clinical Trial Description, 2020
Table 36: RGX-314, Clinical Trial Description, 2020
Table 38: PAN-90806, Clinical Trial Description, 2020
Table 37: Axitinib, Clinical Trial Description, 2020
Table 35: HMR59, Clinical Trial Description, 2020
Table 33: RBM-007, Clinical Trial Description, 2020
Table 39: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in 7MM in USD Million (2017–2030)
Table 40: US Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Table 41: US Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Table 42: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Germany, USD Millions (2017–2030)
Table 43: Germany Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Table 44: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) associated in France, USD Millions (2017–2030)
Table 45: France Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Table 46: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Italy, USD Millions (2017–2030)
Table 47: Italy Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Table 48: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Spain, USD Millions (2017–2030)
Table 49: Spain Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Table 50: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in the UK, USD Millions (2017–2030)
Table 51: UK Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)
Table 52: Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in Japan, USD Millions (2017–2030)
Table 53: Japan Market Size of Wet Form Age-related Macular Degeneration (Wet-AMD) in USD Million (2017–2030)